Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001144204-18-028353
Filing Date
2018-05-15
Accepted
2018-05-14 21:48:23
Documents
64
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q tv493251_10q.htm 10-Q 360545
2 EXHIBIT 31.1 tv493251_ex31-1.htm EX-31.1 8588
3 EXHIBIT 32.1 tv493251_ex32-1.htm EX-32.1 4298
  Complete submission text file 0001144204-18-028353.txt   4054112

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT imnp-20180331.xml EX-101.INS 771310
5 XBRL TAXONOMY EXTENSION SCHEMA imnp-20180331.xsd EX-101.SCH 52414
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE imnp-20180331_cal.xml EX-101.CAL 38348
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE imnp-20180331_def.xml EX-101.DEF 370395
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE imnp-20180331_lab.xml EX-101.LAB 371404
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE imnp-20180331_pre.xml EX-101.PRE 389873
Mailing Address 550 SYLVAN AVENUE, SUITE 101 ENGLEWOOD CLIFFS NJ 07632
Business Address 550 SYLVAN AVENUE, SUITE 101 ENGLEWOOD CLIFFS NJ 07632 201-464-2677
IMMUNE PHARMACEUTICALS INC (Filer) CIK: 0001208261 (see all company filings)

EIN.: 521841431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36602 | Film No.: 18832791
SIC: 2834 Pharmaceutical Preparations